Adma Biologics (ADMA) Assets Average (2011 - 2026)
Adma Biologics' (ADMA) quarterly Assets Average came in at $596.5 million in Q4 2025, up 35.67% YoY from $439.6 million in Q4 2024, and up 5.84% on a QoQ basis from $563.5 million in Q3 2025.
Adma Biologics (ADMA) Assets Average (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Assets Average data on file, last reported at $596.5 million in Q4 2025.
- Quarterly Assets Average rose 35.67% year-over-year to $596.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $596.5 million (up 35.67% YoY) and the FY2025 annual result came in at $556.5 million, up 36.08% from the prior year.
- Assets Average grew to $596.5 million in Q4 2025, from $563.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $596.5 million in Q4 2025 to a low of $221.7 million in Q1 2021.
- A 5-year average of $363.0 million and a median of $341.0 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average surged 94.8% — and 2024, when it retreated 1.33%.
- Tracing ADMA's Assets Average over 5 years: stood at $257.4 million in 2021, then rose by 26.05% to $324.5 million in 2022, then advanced by 4.49% to $339.1 million in 2023, then gained by 29.66% to $439.6 million in 2024, then surged by 35.67% to $596.5 million in 2025.
- The last three Assets Average figures came in at $596.5 million (Q4 2025), $563.5 million (Q3 2025), and $534.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 654.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 654.23 Mn |
| Dec 31, 2025 | 596.46 Mn |
| Sep 30, 2025 | 563.53 Mn |
| Jun 30, 2025 | 534.47 Mn |
| Mar 31, 2025 | 499.62 Mn |
| Dec 31, 2024 | 439.65 Mn |
| Sep 30, 2024 | 383.51 Mn |
| Jun 30, 2024 | 363.64 Mn |
| Mar 31, 2024 | 340.03 Mn |
| Dec 31, 2023 | 339.09 Mn |
| Sep 30, 2023 | 346.01 Mn |
| Jun 30, 2023 | 341.91 Mn |
| Mar 31, 2023 | 344.62 Mn |
| Dec 31, 2022 | 324.51 Mn |
| Sep 30, 2022 | 298.74 Mn |
| Jun 30, 2022 | 302.48 Mn |
| Mar 31, 2022 | 292.14 Mn |
| Dec 31, 2021 | 257.45 Mn |
| Sep 30, 2021 | 235.73 Mn |
| Jun 30, 2021 | 234.24 Mn |